-
1
-
-
33644600485
-
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
-
Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N et al. (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 55: 717-727.
-
(2006)
Cancer Immunol Immunother
, vol.55
, pp. 717-727
-
-
Adams, C.W.1
Allison, D.E.2
Flagella, K.3
Presta, L.4
Clarke, J.5
Dybdal, N.6
-
2
-
-
19044380618
-
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
-
Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI et al. (2002). Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2: 127-137.
-
(2002)
Cancer Cell
, vol.2
, pp. 127-137
-
-
Agus, D.B.1
Akita, R.W.2
Fox, W.D.3
Lewis, G.D.4
Higgins, B.5
Pisacane, P.I.6
-
3
-
-
33748597230
-
Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy
-
June 20
-
Ali SM, Esteva FJ, Fornier M, Gligorov J, Harris L, Kostler WJ et al. (2006). Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy. J Clin Oncol 24(June 20 Supplement): 500.
-
(2006)
J Clin Oncol
, vol.24
, Issue.SUPPL.EMENT
, pp. 500
-
-
Ali, S.M.1
Esteva, F.J.2
Fornier, M.3
Gligorov, J.4
Harris, L.5
Kostler, W.J.6
-
4
-
-
33746290773
-
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation
-
Anido J, Scaltriti M, Bech Serra JJ, Santiago Josefat B, Todo FR, Baselga J et al. (2006). Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO 25: 3234-3244.
-
(2006)
EMBO
, vol.25
, pp. 3234-3244
-
-
Anido, J.1
Scaltriti, M.2
Bech Serra, J.J.3
Santiago Josefat, B.4
Todo, F.R.5
Baselga, J.6
-
5
-
-
31444451572
-
Trastuzumab-based treatment of HER2-positive breast cancer: An antibody-dependent cellular cytotoxicity mechanism?
-
Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C et al. (2006). Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259-267.
-
(2006)
Br J Cancer
, vol.94
, pp. 259-267
-
-
Arnould, L.1
Gelly, M.2
Penault-Llorca, F.3
Benoit, L.4
Bonnetain, F.5
Migeon, C.6
-
6
-
-
0029991439
-
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
-
Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L et al. (1996). Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14: 737-744.
-
(1996)
J Clin Oncol
, vol.14
, pp. 737-744
-
-
Baselga, J.1
Tripathy, D.2
Mendelsohn, J.3
Baughman, S.4
Benz, C.C.5
Dantis, L.6
-
7
-
-
0035169666
-
Mechanism of action of trastuzumab and scientific update
-
Baselga J, Albanell J, Molina MA, Arribas J. (2001). Mechanism of action of trastuzumab and scientific update. Semin Oncol 28(5 Suppl 16): 4-11.
-
(2001)
Semin Oncol
, vol.28
, Issue.5 SUPPL. 16
, pp. 4-11
-
-
Baselga, J.1
Albanell, J.2
Molina, M.A.3
Arribas, J.4
-
8
-
-
27744440126
-
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
-
Burstein HJ, Lieberman G, Slamon DJ, Winer EP, Klein P. (2005). Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol 16: 1772-1777.
-
(2005)
Ann Oncol
, vol.16
, pp. 1772-1777
-
-
Burstein, H.J.1
Lieberman, G.2
Slamon, D.J.3
Winer, E.P.4
Klein, P.5
-
9
-
-
20544460650
-
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
-
Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL et al. (2005). Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23: 3676-3685.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3676-3685
-
-
Buzdar, A.U.1
Ibrahim, N.K.2
Francis, D.3
Booser, D.J.4
Thomas, E.S.5
Theriault, R.L.6
-
10
-
-
0036963448
-
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergisticinhibition of growth in HER2-overexpressing breast cancer cells
-
Camirand A, Lu Y, Pollak M. (2002). Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergisticinhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit 8: BR521-BR526.
-
(2002)
Med Sci Monit
, vol.8
-
-
Camirand, A.1
Lu, Y.2
Pollak, M.3
-
11
-
-
0026610881
-
Humanization of an anti-p185her2 antibody for human cancer therapy
-
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL et al. (1992). Humanization of an anti-p185her2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289.
-
(1992)
Proc Natl Acad Sci USA
, vol.89
, pp. 4285-4289
-
-
Carter, P.1
Presta, L.2
Gorman, C.M.3
Ridgway, J.B.4
Henner, D.5
Wong, W.L.6
-
12
-
-
0032532950
-
NH2-terminally truncated HER-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer
-
Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ et al. (1998). NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58: 5123-5129.
-
(1998)
Cancer Res
, vol.58
, pp. 5123-5129
-
-
Christianson, T.A.1
Doherty, J.K.2
Lin, Y.J.3
Ramsey, E.E.4
Holmes, R.5
Keenan, E.J.6
-
13
-
-
0034076307
-
Inhibitory Fcrec eptors modulate in vivo cytotoxicity against tumor targets
-
Clynes RA, Towers TL, Presta LG, Ravetch JV. (2000). Inhibitory Fcrec eptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6: 443-446.
-
(2000)
Nat Med
, vol.6
, pp. 443-446
-
-
Clynes, R.A.1
Towers, T.L.2
Presta, L.G.3
Ravetch, J.V.4
-
14
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastaticdisease
-
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastaticdisease. J Clin Oncol 17: 2639-2648.
-
(1999)
J Clin Oncol
, vol.17
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
Robert, N.J.4
Scholl, S.5
Fehrenbacher, L.6
-
15
-
-
0034082031
-
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer
-
Colomer R, Montero S, Lluch A, Ojeda B, Barnadas A, Casado A et al. (2000). Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6: 2356-2362.
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2356-2362
-
-
Colomer, R.1
Montero, S.2
Lluch, A.3
Ojeda, B.4
Barnadas, A.5
Casado, A.6
-
16
-
-
0032885461
-
Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu
-
Cooley S, Burns LJ, Repka T, Miller JS. (1999). Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 27: 1533-1541.
-
(1999)
Exp Hematol
, vol.27
, pp. 1533-1541
-
-
Cooley, S.1
Burns, L.J.2
Repka, T.3
Miller, J.S.4
-
17
-
-
33751339625
-
Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells
-
DiGiovanna MP, Chakraborty A. (2006). Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells. Proc Am Assoc Cancer Res 47: 1226.
-
(2006)
Proc Am Assoc Cancer Res
, vol.47
, pp. 1226
-
-
DiGiovanna, M.P.1
Chakraborty, A.2
-
18
-
-
33644528230
-
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
-
Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP et al. (2005). Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7: R436-R443.
-
(2005)
Breast Cancer Res
, vol.7
-
-
Esteva, F.J.1
Cheli, C.D.2
Fritsche, H.3
Fornier, M.4
Slamon, D.5
Thiel, R.P.6
-
19
-
-
0036534121
-
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
-
Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L et al. (2002). Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800-1808.
-
(2002)
J Clin Oncol
, vol.20
, pp. 1800-1808
-
-
Esteva, F.J.1
Valero, V.2
Booser, D.3
Guerra, L.T.4
Murray, J.L.5
Pusztai, L.6
-
20
-
-
1842605531
-
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
-
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317-328.
-
(2004)
Cancer Cell
, vol.5
, pp. 317-328
-
-
Franklin, M.C.1
Carey, K.D.2
Vajdos, F.F.3
Leahy, D.J.4
de Vos, A.M.5
Sliwkowski, M.X.6
-
21
-
-
4444372733
-
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
-
Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E et al. (2004). Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10: 5650-5655.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 5650-5655
-
-
Gennari, R.1
Menard, S.2
Fagnoni, F.3
Ponchio, L.4
Scelsi, M.5
Tagliabue, E.6
-
22
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355: 2733-2743.
-
(2006)
N Engl J Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
-
23
-
-
0030944455
-
ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
-
Graus-Porta D, Beerli RR, Daly JM, Hynes NE. (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO 16: 1647-1655.
-
(1997)
EMBO
, vol.16
, pp. 1647-1655
-
-
Graus-Porta, D.1
Beerli, R.R.2
Daly, J.M.3
Hynes, N.E.4
-
24
-
-
0034813368
-
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662
-
Hayes DF, Yamauchi H, Broadwater G, Cirrincione CT, Rodrigue SP, Berry DA et al. (2001). Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7: 2703-2711.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2703-2711
-
-
Hayes, D.F.1
Yamauchi, H.2
Broadwater, G.3
Cirrincione, C.T.4
Rodrigue, S.P.5
Berry, D.A.6
-
25
-
-
0037149539
-
Tumour biology: Herceptin acts as an anti-angiogenic cocktail
-
Izumi Y, Xu L, di Tomaso E, Fukumura D, Jain RK. (2002). Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416: 279-280.
-
(2002)
Nature
, vol.416
, pp. 279-280
-
-
Izumi, Y.1
Xu, L.2
di Tomaso, E.3
Fukumura, D.4
Jain, R.K.5
-
26
-
-
33746867442
-
Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo
-
Jerome L, Alami N, Belanger S, Page V, Yu Q, Paterson J et al. (2006). Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo. Cancer Res 66: 7245-7252.
-
(2006)
Cancer Res
, vol.66
, pp. 7245-7252
-
-
Jerome, L.1
Alami, N.2
Belanger, S.3
Page, V.4
Yu, Q.5
Paterson, J.6
-
27
-
-
0141787069
-
Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone
-
Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y et al. (2003). Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98: 1377-1385.
-
(2003)
Cancer
, vol.98
, pp. 1377-1385
-
-
Klos, K.S.1
Zhou, X.2
Lee, S.3
Zhang, L.4
Yang, W.5
Nagata, Y.6
-
28
-
-
32944461545
-
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells
-
Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M et al. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639.
-
(2006)
Cancer Res
, vol.66
, pp. 1630-1639
-
-
Konecny, G.E.1
Pegram, M.D.2
Venkatesan, N.3
Finn, R.4
Yang, G.5
Rahmeh, M.6
-
29
-
-
3543146052
-
Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer
-
Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T. (2004). Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10: 1618-1624.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 1618-1624
-
-
Kostler, W.J.1
Schwab, B.2
Singer, C.F.3
Neumann, R.4
Rucklinger, E.5
Brodowicz, T.6
-
30
-
-
0033996361
-
ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: Receptor overexpression does not determine growth dependency
-
Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE. (2000). ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20: 3210-3223.
-
(2000)
Mol Cell Biol
, vol.20
, pp. 3210-3223
-
-
Lane, H.A.1
Beuvink, I.2
Motoyama, A.B.3
Daly, J.M.4
Neve, R.M.5
Hynes, N.E.6
-
31
-
-
0038607569
-
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition
-
Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R et al. (2003). The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem 278: 23441-23450.
-
(2003)
J Biol Chem
, vol.278
, pp. 23441-23450
-
-
XF, L.1
Claret, F.X.2
Lammayot, A.3
Tian, L.4
Deshpande, D.5
LaPushin, R.6
-
32
-
-
0029005754
-
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer
-
Leitzel K, Teramoto Y, Konrad K, Chinchilli VM, Volas G, Grossberg H et al. (1995). Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13: 1129-1135.
-
(1995)
J Clin Oncol
, vol.13
, pp. 1129-1135
-
-
Leitzel, K.1
Teramoto, Y.2
Konrad, K.3
Chinchilli, V.M.4
Volas, G.5
Grossberg, H.6
-
33
-
-
0025829608
-
A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells
-
Lin YZ, Clinton GM. (1991). A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 6: 639-643.
-
(1991)
Oncogene
, vol.6
, pp. 639-643
-
-
Lin, Y.Z.1
Clinton, G.M.2
-
34
-
-
0346154748
-
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells
-
Lu Y, Zi X, Pollak M. (2004). Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334-341.
-
(2004)
Int J Cancer
, vol.108
, pp. 334-341
-
-
Lu, Y.1
Zi, X.2
Pollak, M.3
-
35
-
-
0035915421
-
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
-
Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. (2001). Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857.
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 1852-1857
-
-
Lu, Y.1
Zi, X.2
Zhao, Y.3
Mascarenhas, D.4
Pollak, M.5
-
36
-
-
22344446208
-
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group
-
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M et al. (2005). Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265-4274.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4265-4274
-
-
Marty, M.1
Cognetti, F.2
Maraninchi, D.3
Snyder, R.4
Mauriac, L.5
Tubiana-Hulin, M.6
-
37
-
-
0035874981
-
Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells
-
Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. (2001). Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744-4749.
-
(2001)
Cancer Res
, vol.61
, pp. 4744-4749
-
-
Molina, M.A.1
Codony-Servat, J.2
Albanell, J.3
Rojo, F.4
Arribas, J.5
Baselga, J.6
-
38
-
-
0036187710
-
NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer
-
Molina MA, Saez R, Ramsey EE, Garcia-Barchino MJ, Rojo F, Evans AJ et al. (2002). NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8: 347-353.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 347-353
-
-
Molina, M.A.1
Saez, R.2
Ramsey, E.E.3
Garcia-Barchino, M.J.4
Rojo, F.5
Evans, A.J.6
-
39
-
-
31644439702
-
Herceptin: Mechanisms of action and resistance
-
Nahta R, Esteva FJ. (2006). Herceptin: mechanisms of action and resistance. Cancer Lett 232: 123-138.
-
(2006)
Cancer Lett
, vol.232
, pp. 123-138
-
-
Nahta, R.1
Esteva, F.J.2
-
40
-
-
1942474587
-
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
-
Nahta R, Hung MC, Esteva FJ. (2004a). The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343-2346.
-
(2004)
Cancer Res
, vol.64
, pp. 2343-2346
-
-
Nahta, R.1
Hung, M.C.2
Esteva, F.J.3
-
41
-
-
2542526069
-
P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells
-
Nahta R, Takahashi T, Ueno NT, Hung MC, Esteva FJ. (2004b). P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64: 3981-3986.
-
(2004)
Cancer Res
, vol.64
, pp. 3981-3986
-
-
Nahta, R.1
Takahashi, T.2
Ueno, N.T.3
Hung, M.C.4
Esteva, F.J.5
-
42
-
-
33646712747
-
Mechanisms of Disease: Understanding resistance to HER2-targeted therapy in human breast cancer
-
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. (2006). Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280.
-
(2006)
Nat Clin Pract Oncol
, vol.3
, pp. 269-280
-
-
Nahta, R.1
Yu, D.2
Hung, M.C.3
Hortobagyi, G.N.4
Esteva, F.J.5
-
43
-
-
28244432561
-
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
-
Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. (2005). Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118-11128.
-
(2005)
Cancer Res
, vol.65
, pp. 11118-11128
-
-
Nahta, R.1
Yuan, L.X.2
Zhang, B.3
Kobayashi, R.4
Esteva, F.J.5
-
44
-
-
0034704870
-
Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells
-
Neve RM, Sutterluty H, Pullen N, Lane HA, Daly JM, Krek W et al. (2000). Effects of oncogenic ErbB2 on G1 cell cycle regulators in breast tumour cells. Oncogene 19: 1647-1656.
-
(2000)
Oncogene
, vol.19
, pp. 1647-1656
-
-
Neve, R.M.1
Sutterluty, H.2
Pullen, N.3
Lane, H.A.4
Daly, J.M.5
Krek, W.6
-
45
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672.
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
-
46
-
-
18244422222
-
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
-
Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y et al. (1997). HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 15: 2894-2904.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2894-2904
-
-
Press, M.F.1
Bernstein, L.2
Thomas, P.A.3
Meisner, L.F.4
Zhou, J.Y.5
Ma, Y.6
-
47
-
-
0027524245
-
The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage
-
Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI. (1993). The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8: 2917-2923.
-
(1993)
Oncogene
, vol.8
, pp. 2917-2923
-
-
Pupa, S.M.1
Menard, S.2
Morelli, D.3
Pozzi, B.4
De Palo, G.5
Colnaghi, M.I.6
-
48
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer Jr, C.E.5
Davidson, N.E.6
-
49
-
-
0035873815
-
Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification
-
Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A et al. (2001). Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587-2595.
-
(2001)
J Clin Oncol
, vol.19
, pp. 2587-2595
-
-
Seidman, A.D.1
Fornier, M.N.2
Esteva, F.J.3
Tan, L.4
Kaptain, S.5
Bach, A.6
-
50
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182.
-
(1987)
Science
, vol.235
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
51
-
-
0024337144
-
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
-
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707-712.
-
(1989)
Science
, vol.244
, pp. 707-712
-
-
Slamon, D.J.1
Godolphin, W.2
Jones, L.A.3
Holt, J.A.4
Wong, S.G.5
Keith, D.E.6
-
52
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
-
(2001)
N Engl J Med
, vol.344
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
-
53
-
-
0032851961
-
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin)
-
Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. (1999). Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26(4 Suppl 12): 60-70.
-
(1999)
Semin Oncol
, vol.26
, Issue.4 SUPPL. 12
, pp. 60-70
-
-
Sliwkowski, M.X.1
Lofgren, J.A.2
Lewis, G.D.3
Hotaling, T.E.4
Fendly, B.M.5
Fox, J.A.6
-
54
-
-
12344302247
-
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer
-
Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J et al. (2004). Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3: 1585-1592.
-
(2004)
Mol Cancer Ther
, vol.3
, pp. 1585-1592
-
-
Tanner, M.1
Kapanen, A.I.2
Junttila, T.3
Raheem, O.4
Grenman, S.5
Elo, J.6
-
55
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
-
(2002)
J Clin Oncol
, vol.20
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
Gutheil, J.C.4
Harris, L.N.5
Fehrenbacher, L.6
-
56
-
-
33750584030
-
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: Implications for HER2-targeted antibody therapy
-
Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC et al. (2006). HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 25: 6986-6996.
-
(2006)
Oncogene
, vol.25
, pp. 6986-6996
-
-
Wen, X.F.1
Yang, G.2
Mao, W.3
Thornton, A.4
Liu, J.5
Bast, R.C.6
-
57
-
-
0037068741
-
Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
-
Xia W, Mullin RJ, Keith BR, Liu LH, Ma H, Rusnak DW et al. (2002). Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21: 6255-6263.
-
(2002)
Oncogene
, vol.21
, pp. 6255-6263
-
-
Xia, W.1
Mullin, R.J.2
Keith, B.R.3
Liu, L.H.4
Ma, H.5
Rusnak, D.W.6
-
58
-
-
30544450275
-
Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeuticanti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells
-
Xia W, Gerard CM, Liu L, Baudson NM, Ory TL, Spector NL. (2005). Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeuticanti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells. Oncogene 24: 6213-6221.
-
(2005)
Oncogene
, vol.24
, pp. 6213-6221
-
-
Xia, W.1
Gerard, C.M.2
Liu, L.3
Baudson, N.M.4
Ory, T.L.5
Spector, N.L.6
-
59
-
-
0037099532
-
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action
-
Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. (2002). Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141.
-
(2002)
Cancer Res
, vol.62
, pp. 4132-4141
-
-
Yakes, F.M.1
Chinratanalab, W.2
Ritter, C.A.3
King, W.4
Seelig, S.5
Arteaga, C.L.6
-
60
-
-
0030757466
-
Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein
-
Yamauchi H, O'Neill A, Gelman R, Carney W, Tenney DY, Hosch S et al. (1997). Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 15: 2518-2525.
-
(1997)
J Clin Oncol
, vol.15
, pp. 2518-2525
-
-
Yamauchi, H.1
O'Neill, A.2
Gelman, R.3
Carney, W.4
Tenney, D.Y.5
Hosch, S.6
-
61
-
-
0026071364
-
The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, sk-br-3
-
Zabrecky JR, Lam T, McKenzie SJ, Carney W. (1991). The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, sk-br-3. J Biol Chem 266: 1716-1720.
-
(1991)
J Biol Chem
, vol.266
, pp. 1716-1720
-
-
Zabrecky, J.R.1
Lam, T.2
McKenzie, S.J.3
Carney, W.4
|